Severe Uncontrolled Asthma and Monoclonal Antibodies: An Educational Journey

To participate in this activity, please start here:

Welcome to this question-and-answer activity on key issues related to the targeted treatment of patients with severe uncontrolled asthma. Clinical pearls are provided to select among the 5 monoclonal antibodies currently approved for severe asthma in the United States based upon phenotype and other factors. 

Want to learn more?
Visit Part 1 to learn answers to frequently asked questions on monoclonal antibody agents for severe asthma.

Course Credit:

0.50 AANP Contact Hour
0.50 AMA PRA Category 1 CreditTM

Dates:

Opens: 2020-06-30
Closes: 2021-07-01

Target Audience:

This activity is intended for allergists, pulmonologists, and other clinicians interested in the management of patients with severe uncontrolled asthma.

This activity is supported by an independent educational grant from GlaxoSmithKline.
  • Reynold A. Panettieri, Jr, MD

    Vice Chancellor, Translational Medicine and Science
    Director, Rutgers Institute for Translational Medicine and Science
    Professor of Medicine, Rutgers University
    New Brunswick, New Jersey
    Emeritus Professor of Medicine, University of Pennsylvania

Learning Objectives

  • Appraise the latest developments, including monoclonal antibody therapies, in the treatment of patients with severe uncontrolled asthma
  • Differentiate between currently available monoclonal antibody therapy for severe uncontrolled asthma
  • Assess and integrate factors determining the choice of monoclonal antibody therapy for patients with severe uncontrolled asthma

Faculty Disclosures

Reynold A. Panettieri, Jr, MD

Research Support

  • AstraZeneca – clinical area: Pulmonary Disease
  • MedImmune – clinical area: Pulmonary Disease
  • RIFM – clinical area: Pulmonary Disease
  • Equillium – clinical area: Pulmonary Disease
  • Genentech – clinical area: Pulmonary Disease
  • Metera – clinical area: Pulmonary Disease

Consultant

  • AstraZeneca – clinical area: Pulmonary Disease
  • MedImmune – clinical area: Pulmonary Disease
  • RIFM – clinical area: Pulmonary Disease
  • Equillium – clinical area: Pulmonary Disease
  • Theravance – clinical area: Pulmonary Disease
  • Avillion – clinical area: Pulmonary Disease

Speakers Bureau

  • AstraZeneca – clinical area: Pulmonary Disease
  • Sanofi – clinical area: Pulmonary Disease
  • Genentech – clinical area: Pulmonary Disease

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is designated for up to 0.50 contact hour. Program ID# 5811-EM.

Additional Content Planners

Juan Cardet, MD (Peer Reviewer)
No significant relationships to disclose.

Heather M. Jimenez, FNP-C (Nurse Planner)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.